<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This retrospective study investigated the clinical characteristics of patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) depending on the KRAS status, thereby differentiating KRAS exon 2 mutations in codon 12 versus codon 13 </plain></SENT>
<SENT sid="1" pm="."><plain>In total, 273 patients with mCRC receiving first-line therapy were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>One hundred patients were treated within the FIRE-3 trial (FOLFIRI plus cetuximab or bevacizumab), 147 patients within the AIO KRK-0104 trial (cetuximab plus CAPIRI or CAPOX), and further 26 patients received therapy outside the study </plain></SENT>
<SENT sid="3" pm="."><plain>Thirty-eight <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with KRAS mutation in codon 13, 140 tumors with mutation in codon 12, and 95 tumors with KRAS <z:mp ids='MP_0002169'>wild type</z:mp> as a comparison were included in this analysis </plain></SENT>
<SENT sid="4" pm="."><plain>Bivariate analyses demonstrated significant differences between KRAS <z:mp ids='MP_0002169'>wild-type</z:mp>, codon 12-mutated, and codon 13-mutated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with regard to synchronous lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P=0.018), organ <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (76.8% vs. 65.9% vs. 89.5%, P=0.009), <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> (89.5% vs. 78.2% vs. 92.1%, P=0.025), lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (29.5% vs. 42.9% vs. 50%, P=0.041), liver-only <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (48.4% vs. 28.8% vs. 28.9%, P=0.006), and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> in two or more organs (49.5, 61.4, 71.1, P=0.047) </plain></SENT>
<SENT sid="5" pm="."><plain>Regression models indicated a significant impact of KRAS mutations in codon 12 versus codon 13 for synchronous organ and nodal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (P=0.01, 0.03) </plain></SENT>
<SENT sid="6" pm="."><plain>This pooled analysis indicates that mCRC is a <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> disease, which seems to be defined by KRAS mutations of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with KRAS codon 12 mutations, codon 13-mutated mCRC presents as a more <z:e sem="disease" ids="C0001807" disease_type="Mental or Behavioral Dysfunction" abbrv="">aggressive disease</z:e> frequently associated with local and distant <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> at first diagnosis </plain></SENT>
</text></document>